All patients
Age < 65y (younger) Age > 65y Asian type EGFR mutation Ex19del EGFR mutation L858R Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2), ... vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results AURA3, 2017 0.87 [0.64; 1.18]
CAURAL (EXPLORATORY), 2019 (REV) 0.38 [0.06; 2.54]
Nie, 2018 0.79 [0.38; 1.63]
0.84 [0.64 ; 1.11 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV), Nie, 2018 3 0% 595 moderate not evaluable progression or deaths (PFS)detailed results AURA3, 2017 0.30 [0.22; 0.40]
CAURAL (EXPLORATORY), 2019 (REV) 0.91 [0.18; 4.64]
Nie, 2018 0.23 [0.13; 0.41]
0.29 [0.21 ; 0.42 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV), Nie, 2018 3 22% 595 moderate not evaluable DCRdetailed results AURA3, 2017 3.85 [2.18; 6.82]
3.85 [2.18 ; 6.82 ] AURA3, 2017 1 0% 419 NA not evaluable objective responses (ORR)detailed results AURA3, 2017 5.39 [3.45; 8.43]
CAURAL (EXPLORATORY), 2019 (REV) 2.22 [0.42; 11.83]
Nie, 2018 17.33 [6.66; 45.11]
6.71 [2.57 ; 17.49 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV), Nie, 2018 3 68% 595 moderate not evaluable AE (any grade)detailed results AURA3, 2017 0.34 [0.04; 2.83]
CAURAL (EXPLORATORY), 2019 (REV) 0.70 [0.01; 37.74]
0.40 [0.06 ; 2.59 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV) 2 0% 444 moderate not evaluable AE (grade 3-4)detailed results AURA3, 2017 0.31 [0.20; 0.48]
CAURAL (EXPLORATORY), 2019 (REV) 0.08 [0.01; 0.77]
0.25 [0.10 ; 0.65 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV) 2 24% 444 moderate not evaluable AE leading to death (grade 5)detailed results AURA3, 2017 1.96 [0.22; 17.74]
CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.83 [0.27 ; 12.54 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV) 2 0% 444 moderate not evaluable SAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.61 [0.12; 3.16]
0.61 [0.12 ; 3.16 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable STRAE (any grade)detailed results CAURAL (EXPLORATORY), 2019 (REV) 3.00 [0.09; 97.33]
3.00 [0.09 ; 97.33 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable TRAE (any grade)detailed results AURA3, 2017 0.60 [0.32; 1.11]
CAURAL (EXPLORATORY), 2019 (REV) 0.43 [0.08; 2.42]
0.57 [0.32 ; 1.03 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV) 2 0% 444 moderate not evaluable TRAE (grade 3-4)detailed results AURA3, 2017 0.12 [0.06; 0.22]
CAURAL (EXPLORATORY), 2019 (REV) 0.14 [0.01; 2.97]
0.12 [0.07 ; 0.22 ] AURA3, 2017, CAURAL (EXPLORATORY), 2019 (REV) 2 0% 444 moderate not evaluable TRAE leading to death (grade 5)detailed results Nie, 2018 0.99 [0.02; 50.39]
0.99 [0.02 ; 50.39 ] Nie, 2018 1 0% 147 NA not evaluable Arthralgia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Back pain AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Constipation AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Cough AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Diarrhoea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.70 [0.02; 22.54]
0.70 [0.02 ; 22.54 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Dry skin AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Dyspnoea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Nausea AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Neutropenia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.33 [0.01; 7.94]
0.33 [0.01 ; 7.94 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Pneumonia AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 0.33 [0.01; 7.94]
0.33 [0.01 ; 7.94 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Pruritus AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Rash AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable Stomatitis AE (grade 3-4)detailed results CAURAL (EXPLORATORY), 2019 (REV) 1.43 [0.03; 77.69]
1.43 [0.03 ; 77.69 ] CAURAL (EXPLORATORY), 2019 (REV) 1 0% 29 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-04 15:07 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169
- treatments: 431
